PIUS EFOBI: Open Payments
NPI 1306538707 · LONG BRANCH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,324 in 147 payments from 11 companies in 2025. Trend: 2023 $192 · 2024 $2,512 · 2025 $2,324
Food & beverage: $2,212Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 77 | $761 |
| Otsuka America Pharmaceutical, Inc. | 15 | $299 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $293 |
| Alkermes, Inc. | 8 | $260 |
| Teva Pharmaceuticals USA, Inc. | 10 | $218 |
| Janssen Pharmaceuticals, Inc | 9 | $171 |
| Neurocrine BioSciences, Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $61 |
Products named: VRAYLAR, CAPLYTA, REXULTI, LYBALVI, SPRAVATO, INGREZZA, AUSTEDO XR, ARISTADA.
Industry payments across NJ — which companies pay providers there.
